AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$TENX

TENAX THERAPEUTICS, INC.

Price · $TENXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TENX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $TENX in the last 30 days.

Top stories · $TENXMore →
APR 22·Stock TitanLow

Tenax Therapeutics (NASDAQ: TENX) 2026 proxy details director slate, auditor vote

Tenax Therapeutics (NASDAQ: TENX) has issued its definitive proxy statement for its 2026 Annual Meeting of Stockholders, scheduled for June 2, 2026. Shareholders will vote on the election of seven directors for one-year terms and the ratification of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board of Directors unanimously recommends a "FOR" vote on both proposals, detailing executive compensation, board structure, and key financial metrics including CEO salary and stock option grants.

MAR 4·MarketBeat

Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving Average - Here's What Happened

Tenax Therapeutics (NASDAQ:TENX) recently saw its shares cross above its 200-day moving average, trading at $11.42 with significant volume. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average target price of $21.67, including a raised target of $25 from Guggenheim. Insider Stuart Rich and several hedge funds, such as Perceptive Advisors, have increased their holdings in the company, signaling confidence in its prospects.

FEB 21·GuruFocus

RTW INVESTMENTS, LP Acquires Additional Shares in Tenax Therapeu

RTW INVESTMENTS, LP increased its stake in Tenax Therapeutics Inc. by acquiring an additional 272,622 shares on December 31, 2025, bringing its total holdings to 650,968 shares. This strategic move, valued at $12.19 per share, reflects RTW's confidence in the specialty pharmaceutical company despite its current financial challenges. Tenax Therapeutics Inc. focuses on cardiovascular and pulmonary diseases and is advancing clinical trials for levosimendan, aligning with RTW INVESTMENTS, LP's healthcare-focused investment strategy.

News on $TENX